Cidara's Once-Weekly Antifungal Gets Phase III Boost From Mundipharma

 
• By John Davis

Mundipharma is to provide financial support and development expertise for Cidara’s Phase III clinical studies of its once-weekly echinocandin antifungal for serious infections, in return for ex-US and ex-Japanese marketing rights.  

Mold
Aspergillus can cause fungal infections in patients • Source: Shutterstock

More from Anti-infective

More from Therapy Areas